- Phase 2 trial enrollment on schedule in PNH combo, interim data expected in Q2:2019 - - Phase 2 trial enrollment on schedule in C3G, 24 sites recruiting - - Next-generation factor D inhibitor ACH-5228 US IND anticipated in Q4:2019 - - Reduced 2018 net cash spend to $60 million , projecting $80
NEW HAVEN, Conn. , Feb. 21, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office
NEW HAVEN, Conn. , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt , President and
NEW HAVEN, Conn. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced the appointment of Brian Di Donato
- ACH-5228, with improved potency and half-life, increases alternative pathway inhibition - - Achillion planning Investigational New Drug (IND) submission in fourth quarter of 2019 - NEW HAVEN, Conn. , Jan. 31, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc.
Nicole Vitullo Brings Public Company Investment and Leadership Expertise as the next Chair of Achillion Board of Directors NEW HAVEN, Conn. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the
ACH-4471, First Generation Oral factor D Inhibitor - Proof of Concept Validated in both PNH as Monotherapy and in Combination w/C5 Inhibitor - Proof of Mechanism Validated in C3G, End of Phase 2 Meeting Targeted for 4Q 2019 ACH-5228, Next Generation Oral factor D Inhibitor - Data Demonstrate 3x to
NEW HAVEN, Conn. , Dec. 10, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company focused on advancing its orally administered factor D complement inhibitors into late-stage development and commercialization, announced today that the
- Completed enrollment of Phase 2 clinical trial of ACH-4471 in PNH as monotherapy - - Interim data and strategic update planned for December 17, 2018 – - September 30, 2018 cash & securities position of $283 million – - Mary Kay Fenton to step down as CFO at year-end 2018 - NEW HAVEN, Conn.
NEW HAVEN, Conn. , Sept. 25, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) announced today that Joseph Truitt , President and Chief Executive Officer of Achillion, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on Tuesday, October 2, 2018 ,